Elecoglipron dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Elecoglipron is AstraZeneca's daily GLP-1 pill. People lost 10.5 percent of their weight in 26 weeks in a mid-stage study. Large final-stage studies are starting.
Evidence grade for Elecoglipron: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 2 completed trials, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 2
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 0 people given it
1 effects reported, 1 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Elecoglipron is a daily GLP-1 pill from AstraZeneca. You swallow it instead of injecting it. It is not approved. Large final-stage studies are starting.
What people take it for
- GLP-1 weight loss without a needle.
- Lower blood sugar in type 2 diabetes.
What studies in people showed
The main study had 310 adults and ran 26 weeks. On 75 mg, people lost 10.5 percent of their weight. People on a dummy pill lost 0.6 percent. Six months is short for a weight drug. AstraZeneca has announced large studies in obesity, in diabetes, and on heart and kidney events. None has reported.
What people report
Reports, not study results
The good
- In the study on this page, the pill took off about a tenth of body weight in six months.
The bad
- The study on this page does not list side effects, and we have not collected user reports on this one yet.
Where these come from: The good line is from the study on this page. We have not collected forum or user reports for this drug yet.
My bottom line
It works, and so far it takes off less than the shots. It is not approved. Check your blood sugar first, then ask your doctor what is actually on offer.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Elecoglipron has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weightno headcount stated · 1 study
35 of the 36 indexed goals have no study of any kind behind Elecoglipron
No study in people, animals or cells on this page reports a result for these. That does not prove Elecoglipron does nothing for them. It does mean anything you have heard about Elecoglipron and one of these did not come from a study cited here.
Show full evidence
What is Elecoglipron?
Elecoglipron is AstraZeneca's daily GLP-1 pill. People lost 10.5 percent of their weight in 26 weeks in a mid-stage study. Large final-stage studies are starting.
Elecoglipron is a GLP-1 drug in pill form, licensed from Eccogene. In a mid-stage study called VISTA, 310 adults took it. On 75 mg they lost 10.5 percent of their weight in 26 weeks. People on a dummy pill lost 0.6 percent. It was published in The Lancet and presented at the American Diabetes Association meeting in 2026. AstraZeneca announced large final-stage studies in obesity, in type 2 diabetes, and on heart and kidney events. It also plans to pair it with its own amylin drug, AZD6234.
How does Elecoglipron work?
It is a small molecule that turns on the GLP-1 signal. It is taken as a pill once a day.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 880.9 Da
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for Elecoglipron, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2026Elecoglipron, an oral small-molecule GLP-1 receptor agonist, in obesity (VISTA)
The pill worked, and the effect is real but smaller than the injections deliver. 310 adults took elecoglipron or a dummy pill daily for half a year. On the 75 mg dose the average person lost about a tenth of their body weight. The dummy group lost almost nothing. Six months is a short run for a weight drug, and the injected drugs are usually judged after a year or more.
10.5% weight loss at 26 weeks on 75 mg versus 0.6% placebo.
- Study in people2026Elecoglipron moves to Phase III programme
Nothing has been published from these trials yet. AstraZeneca announced it was taking elecoglipron into large final-stage studies in obesity, in type 2 diabetes, and in trials that count heart and kidney events. That last kind matters most, because it measures what happens to people rather than what happens on the scale. All of this is announcement, not result.
Phase 3 in obesity, diabetes, and outcomes trials.
Common questions
Has Elecoglipron been tested in people?
Yes. 0 people given it across 2 completed trials cited here, 0 of which found nothing. Elecoglipron is AstraZeneca's daily GLP-1 pill. People lost 10.5 percent of their weight in 26 weeks in a mid-stage study. Large final-stage studies are starting.
What is the Elecoglipron dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 2 completed trials, 0 people given it
Is Elecoglipron FDA-approved?
Investigational; final-stage studies announced in 2026
Which oral GLP-1 pills exist in 2026?
Orforglipron is approved. Aleniglipron, elecoglipron and HRS-7535 are in large final-stage studies. Danuglipron was dropped. The Wegovy pill, which is semaglutide by mouth, is a peptide drug in pill form, not a small molecule.
Latest reading on Elecoglipron
Blog posts about Elecoglipron, newest first.